Anupam Rasayan India Ltd share price
NSE: ANURAS · ISIN INE930P01018
Key numbers
- Market cap
- ₹ 13,576 Cr
- Current price
- ₹ 1,192.40
- 52-week high / low
- ₹ 1,415 / 1,045
- Stock P/E
- 76.3
- Book value
- ₹ 293.1
- Dividend yield
- 0.13%
- ROCE
- 8.4%
- ROE
- 5.5%
- Debt to equity
- 0.57
- Sales growth (3 yrs)
- 14.1%
- Profit growth (3 yrs)
- -2.0%
- 1-year return
- 9.1%
About Anupam Rasayan India Ltd
Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments: Life Science related Specialty Chemicals and Other Specialty Chemicals. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates and key starting materials for active pharmaceutical ingredients. It provides other specialty chemicals used in various end-user segments, including specialty pigments, specialty dyes, and polymer additives. The company was incorporated in 1984 and is headquartered in Surat, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 500 | 486 | 512 | 636 | 655 |
| Operating profit | 144 | 124 | 127 | 137 | 162 |
| Net profit | 45 | 34 | 49 | 43 | 39 |
| EPS (₹) | 4.06 | 3.10 | 4.31 | 3.75 | 3.39 |
Concall summary (2026-08-20)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- We are pleased to begin FY27 on a strong note with consolidated total income growing by 36% year- on-year.
- With this, our cumulative signed LOI and contracts highlighted in the presentation represents roughly INR18,000 crores of potential business over their respective tenures with several new products scheduled for commercialization from FY27 onwards.
Growth & demand
- The potential long-term opportunity of approximately USD300 million spread over a period of 10 years reflects the depth of our customer engagement and our ability to participate in em erging high- growth application.
- Consolidated total income for Q1 FY27 stood at INR668 crores, representing a growth of 36% year -on-year.
Margins & costs
- Consolidated EBITDA increased 35% year -on-year to INR175 crores, with EBITDA margins maintained at 26%.
- Consolidated EBITDA for the quarter stood at INR174.9 crores compared to INR129.2 crores in Q1 FY26, representing a growth of 35% year-on-year.
Capex & expansion
- On the strategic front, our Jayhawk acquisition is already strengthening our global platform.
- On the capex front, we have now completed the major capex cycle that we had undertaken over the last few years.
Balance sheet & cash
- We expect this changing mix together with tighter inventory and receivable management to su pport further improvement in working capital efficiency over time.
- So on the working capital side, our working capital has been remaining stable, as Amit also mentioned in his opening remarks, that working capital has been stable and we are on the trajectory that we have been guiding there.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.